<p>ESSA Pharma Inc. has announced that, following its acquisition by XenoTherapeutics, it has requested the Nasdaq Capital Market to file a delisting application for its common shares. The company expects to terminate registration of its shares approximately 10 days after the closing of the acquisition, which was completed on October 9, 2025. An early warning report regarding the transaction will be filed on SEDAR+. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ESSA Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-098078), on October 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

EPIX

<p>ESSA Pharma Inc. will be delisted from the Nasdaq following its acquisition by XenoTherapeutics. The company has requested a delisting application for its common shares, expecting to terminate registration approximately 10 days after the acquisition's completion on October 9, 2025. An early warning report regarding the transaction will be filed on SEDAR+.</p>

ESSA Pharma Inc to be delisted from Nasdaq following acquisition by XenoTherapeutics